Indiana hasn’t reached the peak of the opioid epidemic yet.
Adam Wren7 min read
The Unblinding: Has Lilly Solved the Alzheimer’s Puzzle? — An Epilogue
The search continues.
Adam Wren5 min read
The Unblinding: Has Lilly Solved The Alzheimer’s Puzzle?
Eli Lilly and Company has spent three decades and $3 billion in an Ahab-like quest to develop the world’s first effective drug to treat Alzheimer’s disease.
Adam Wren29 min read
Getting Right: The Long, Slow Recovery of Austin, Indiana
Austin has become a mecca for illegal drug use and crime. The problem was painfully highlighted by the HIV outbreak that hit this spring.
Evan West22 min read
Survey Says: Indy Top Doctors Answer Burning Questions
“I wish my patients wouldn’t bash the Affordable Care Act while benefiting from it.”
Megan Fernandez6 min read
Hot-Button Issues: The Straight Dope
Indianapolis is drawing heroin straight from Mexico and bypassing Chicago altogether—which might account for the high potency.
IM Editors3 min read
The Undercover Files: Narcotics
“I was introduced to an Outlaws biker once when I was buying meth. The guy pulled out a .44 black powder pistol that was almost a foot long and set it on the table to intimidate me.”
Daniel S. Comiskey2 min read
IM Crime Files: The Scourge
Editor’s Note: The following originally appeared in the October 2005 “Small Towns” issue and is included among IM’s Best-Ever Crime Stories.
Tony Rehagen46 min read
Life after Zyprexa: the Future of Eli Lilly and Company
“We want high quality of life as long as possible, don’t we?” says Lilly executive Jan Lundberg. “Many of our current diseases are chronic, and they accumulate with age, so there are major demands coming from the aging population.”
Evan West5 min read
With thousands of medical success stories and billions in revenue, officials at Lilly are still celebrating the success of Zyprexa. But its troubled path reveals volumes about how difficult bringing even an approved medication to market can turn out to be.